GT Biopharma Inc (GTBP)

$0.31 +0.00 (1.59%)
Market Cap 14.04M
Revenue (ttm) 0.00
Net Income (ttm) -28.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 406,514
Avg Vol 1,334,360
Day's Range N/A - N/A
Shares Out 44.34M
Stochastic %K 22%
Beta 0.84
Analysts Sell
Price Target $3.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumo...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 919 4040
Address:
315 Montgomery Street, 10th Floor, San Francisco, United States
topstockalerts
topstockalerts Jul. 25 at 12:25 AM
After Hours Top Gainers PT2 $LSE $OMH $HIHO $GTBP $JBDI
0 · Reply
topstockalerts
topstockalerts Jul. 16 at 7:48 PM
$GTBP there’s a certain stubbornness to this strength.
0 · Reply
Traildog19
Traildog19 Jul. 14 at 2:38 PM
$GTBP when r/s?
0 · Reply
NathanNat
NathanNat Jul. 13 at 5:17 PM
$GTBP for all you newbies - welcome to the death spiral!
1 · Reply
Cancercrusader
Cancercrusader Jul. 7 at 1:02 PM
$GTBP Reverse split incoming
0 · Reply
Sween_Dog
Sween_Dog Jun. 30 at 7:14 PM
$GTBP some day maybe my .55 average won’t be such a bad thing
0 · Reply
huggenberg
huggenberg Jun. 30 at 6:21 PM
$IBRX $GTBP We’ll find out what happens.
3 · Reply
todn
todn Jun. 25 at 1:20 PM
$GTBP watching this one may collaborate with $IBRX
0 · Reply
Cancercrusader
Cancercrusader Jun. 25 at 12:42 PM
$GTBP $IBRX Nanobodies: The puzzle is coming together. https://x.com/MK2forU/status/2070112971137699849 In with 20k
0 · Reply
BrianScully
BrianScully Jun. 22 at 7:40 PM
$GTBP
0 · Reply
Latest News on GTBP
GT Biopharma Proxy statement: Proxy filing

Jul 2, 2026, 8:00 AM EDT - 4 weeks ago

GT Biopharma Proxy statement: Proxy filing

GT Biopharma Proxy statement: Proxy filing

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

GT Biopharma Proxy statement: Proxy filing

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Jun 8, 2026, 9:01 AM EDT - 7 weeks ago

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

Jun 1, 2026, 8:00 AM EDT - 2 months ago

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

May 15, 2026, 8:00 AM EDT - 2 months ago

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

GT Biopharma Quarterly report: Q1 2026

GT Biopharma Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

GT Biopharma Earnings release: Q1 2026

GT Biopharma doses first patient in GTB-5550 trial

2026-05-14T14:05:26.000Z - 2 months ago

GT Biopharma doses first patient in GTB-5550 trial

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

May 14, 2026, 8:30 AM EDT - 2 months ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GT Biopharma files to sell 9.72M shares of common stock for holders

2026-04-30T21:13:17.000Z - 3 months ago

GT Biopharma files to sell 9.72M shares of common stock for holders

GT Biopharma Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

GT Biopharma Registration statement: Registration filing

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 2:00 PM EDT - 3 months ago

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

GT Biopharma Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

GT Biopharma Slides: Corporate presentation

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-03T13:31:45.000Z - 5 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T21:36:20.000Z - 5 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

GT Biopharma expects cash to fund operations through Q4 2026

2026-03-02T12:12:33.000Z - 5 months ago

GT Biopharma expects cash to fund operations through Q4 2026

GT Biopharma Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 5 months ago

GT Biopharma Reports Full Year 2025 Financial Results

GT Biopharma Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

GT Biopharma Earnings release: Q4 2025

GT Biopharma Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

GT Biopharma Annual report: Q4 2025

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Feb 17, 2026, 7:30 AM EST - 5 months ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

GT Biopharma announces FDA clearance of IND application for GTB-5550

2026-02-03T13:35:12.000Z - 6 months ago

GT Biopharma announces FDA clearance of IND application for GTB-5550

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Feb 3, 2026, 8:30 AM EST - 6 months ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GT Biopharma Registration statement: Registration Filing

Jan 21, 2026, 7:00 AM EST - 6 months ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

2026-01-15T13:36:22.000Z - 7 months ago

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Jan 15, 2026, 8:30 AM EST - 7 months ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Dec 19, 2025, 7:44 AM EST - 7 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 19, 2025, 8:00 AM EST - 9 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

GT Biopharma price target lowered to $8 from $11 at Roth Capital

2025-11-17T13:10:48.000Z - 9 months ago

GT Biopharma price target lowered to $8 from $11 at Roth Capital

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

2025-11-14T14:05:16.000Z - 9 months ago

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Quarterly report: Q3 2025

GT Biopharma Earnings release: Q3 2025

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Earnings release: Q3 2025

GT Biopharma files to sell 14.59M shares of common stock for holders

2025-10-24T20:20:16.000Z - 9 months ago

GT Biopharma files to sell 14.59M shares of common stock for holders

GT Biopharma Registration statement: Registration Filing

Oct 24, 2025, 8:00 AM EDT - 9 months ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

2025-10-08T13:10:29.000Z - 10 months ago

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 11 months ago

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 1 year ago

GT Biopharma Reports Second Quarter 2025 Financial Results

GT Biopharma Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Earnings release: Q2 2025

GT Biopharma Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Quarterly report: Q2 2025

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

2025-08-11T11:21:57.000Z - 1 year ago

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Aug 11, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GT Biopharma Registration statement: Registration Filing

Jun 27, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma appoints Mun-Gavin to board of directors

2025-06-13T13:10:35.000Z - 1 year ago

GT Biopharma appoints Mun-Gavin to board of directors

GT Biopharma Appoints New Member to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma files to sell 120.55M shares of common stock for holders

2025-06-11T21:40:29.000Z - 1 year ago

GT Biopharma files to sell 120.55M shares of common stock for holders

GT Biopharma Registration statement: Registration Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

2025-05-19T13:10:50.000Z - 1 year ago

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

GT Biopharma Quarterly report: Q1 2025

GT Biopharma appoints Andrew Ritter to board of directors

2025-05-15T13:16:23.000Z - 1 year ago

GT Biopharma appoints Andrew Ritter to board of directors

GT Biopharma Slides: Corporate Presentation

May 15, 2025, 6:00 AM EDT - 1 year ago

GT Biopharma Slides: Corporate Presentation

GT Biopharma appoints Kramer to board of directors

2025-05-14T11:32:30.000Z - 1 year ago

GT Biopharma appoints Kramer to board of directors

GT Biopharma files to sell 625,283 shares of common stock for holders

2025-03-06T22:25:27.000Z - 1 year ago

GT Biopharma files to sell 625,283 shares of common stock for holders

GT Biopharma Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Announces Exercise of Warrants

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

2025-02-25T17:40:40.000Z - 1 year ago

GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

GT Biopharma announces request for withdrawal of Form S-1 registration statement

2025-02-25T12:30:51.000Z - 1 year ago

GT Biopharma announces request for withdrawal of Form S-1 registration statement

GT Biopharma Annual report: Q4 2024

Feb 21, 2025, 3:00 PM EST - 1 year ago

GT Biopharma Annual report: Q4 2024

GT Biopharma Registration statement: Registration Filing

Feb 7, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Registration statement: Registration Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Registration statement: Registration Filing

Dec 23, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Slides: Corporate Presentation

Nov 19, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Slides: Corporate Presentation

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Quarterly report: Q3 2024

GT Biopharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Earnings release: Q3 2024

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Sep 24, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q2 2024

GT Biopharma Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q2 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma Registration statement: Registration Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Registration statement: Registration Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Proxy statement: Proxy Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

May 20, 2024, 10:43 AM EDT - 2 years ago

What made GT Biopharma stock more than double on Monday?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q1 2024

GT Biopharma Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q1 2024

GT Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma Annual report: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Annual report: Q4 2023

GT Biopharma Earnings release: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q4 2023

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

GT Biopharma Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q3 2023

GT Biopharma Earnings release: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q3 2023

GT Biopharma Proxy statement: Proxy Filing

Oct 27, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

GT Biopharma Quarterly report: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q2 2023

GT Biopharma Earnings release: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q2 2023

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Aug 3, 2023, 1:25 PM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

GT Biopharma Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q1 2023

GT Biopharma Earnings release: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q1 2023

GT Biopharma Proxy statement: Proxy Filing

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Proxy statement: Proxy Filing

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

GT Biopharma Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

GT Biopharma Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Annual report: Q4 2022

GT Biopharma Earnings release: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q4 2022

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 3:15 PM EST - 4 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 4 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 5:15 PM EDT - 4 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Quarterly report: Q3 2022

Oct 31, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Quarterly report: Q3 2022

GT Biopharma Earnings release: Q3 2022

Oct 31, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Earnings release: Q3 2022

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 25, 2022, 2:44 PM EDT - 4 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

GT Biopharma Registration statement: Registration Filing

Oct 13, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Registration statement: Registration Filing

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 6, 2022, 8:18 AM EDT - 4 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 4:10 PM EDT - 4 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

GT Biopharma Proxy statement: Proxy Filing

Oct 4, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 12, 2022, 9:34 AM EDT - 4 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Sep 8, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 30, 2022, 6:00 PM EDT - 4 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma Proxy statement: Proxy Filing

Aug 17, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Proxy statement: Proxy Filing

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 9:35 AM EDT - 4 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Quarterly report: Q2 2022

GT Biopharma Earnings release: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Earnings release: Q2 2022

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

topstockalerts
topstockalerts Jul. 25 at 12:25 AM
After Hours Top Gainers PT2 $LSE $OMH $HIHO $GTBP $JBDI
0 · Reply
topstockalerts
topstockalerts Jul. 16 at 7:48 PM
$GTBP there’s a certain stubbornness to this strength.
0 · Reply
Traildog19
Traildog19 Jul. 14 at 2:38 PM
$GTBP when r/s?
0 · Reply
NathanNat
NathanNat Jul. 13 at 5:17 PM
$GTBP for all you newbies - welcome to the death spiral!
1 · Reply
Cancercrusader
Cancercrusader Jul. 7 at 1:02 PM
$GTBP Reverse split incoming
0 · Reply
Sween_Dog
Sween_Dog Jun. 30 at 7:14 PM
$GTBP some day maybe my .55 average won’t be such a bad thing
0 · Reply
huggenberg
huggenberg Jun. 30 at 6:21 PM
$IBRX $GTBP We’ll find out what happens.
3 · Reply
todn
todn Jun. 25 at 1:20 PM
$GTBP watching this one may collaborate with $IBRX
0 · Reply
Cancercrusader
Cancercrusader Jun. 25 at 12:42 PM
$GTBP $IBRX Nanobodies: The puzzle is coming together. https://x.com/MK2forU/status/2070112971137699849 In with 20k
0 · Reply
BrianScully
BrianScully Jun. 22 at 7:40 PM
$GTBP
0 · Reply
splitsoup
splitsoup Jun. 18 at 9:28 PM
$GTBP still holding my full position on this one. Up 12% so far.
0 · Reply
MTrade203
MTrade203 Jun. 18 at 7:15 PM
$GTBP Finally dumped 6/1 purchase of this rock with 1.9% gain.
0 · Reply
Investing4Knowledge
Investing4Knowledge Jun. 15 at 4:43 AM
$SRXH + $GTBP if you tryna bank tomorrow here are your 2 plays locked and loaded 🔒 🚀 $SPY $QQQ $BTC.X
0 · Reply
Investing4Knowledge
Investing4Knowledge Jun. 12 at 5:04 PM
$SRXH - I am ready for $0.15+ next week 🚀 My tiny $SPCX allocation won’t bring me much $ satisfaction but my 200,000 shares of SRXH and $GTBP certainly might 😂
2 · Reply
focafoca99
focafoca99 Jun. 8 at 1:27 PM
$GTBP announced its third TriKE candidate entered the clinic with first patient dosed in a Phase 1 trial of GTB-5550, expanding into solid
0 · Reply
Traildog19
Traildog19 Jun. 3 at 2:18 AM
$GTBP is R/S in the cards?
0 · Reply
YeboGogo
YeboGogo Jun. 2 at 7:45 PM
$GTBP seems worth a small punt
0 · Reply
focafoca99
focafoca99 Jun. 2 at 7:20 PM
$GTBP started its third TriKE candidate trial as the first patient was dosed in the Phase 1 study of GTB-5550.
0 · Reply
Lukey63
Lukey63 Jun. 2 at 4:12 PM
$GTBP Highly speculative, needs funding, but added to portfolio today. Since the beginning of the year Vanguard has added 700m shares, other institutions have added smaller amounts. I see no significant selling.
1 · Reply
splitsoup
splitsoup Jun. 1 at 2:24 PM
$GTBP on strong watch!
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:55 PM
$GTBP 07:35 on Jun. 01 2026 EXCLUSIVE: GT Biopharma Implements AI Initiatives To Accelerate Pipeline Discovery, Reduce Costs, Explores Opportunities Beyond Oncology #tradeideas
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:54 PM
$GTBP 07:31 on Jun. 01 2026 EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout #tradeideas
0 · Reply